CTLA4 and melanoma: It was in 2011, with the FDA’s approval of ipilimumab, a cytotoxic T-lymphocyte associated protein 4 (CTLA-4)-targeting immune checkpoint inhibitor (ICI) for the treatment of melanoma that cancer immunotherapy entered a renaissance.